Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding…


Previous articlePT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and Altered States of Consciousness Meet
Next articleCOMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer